Drug Approval | May 15, 2022
USFDA approves novel, dual-targeted treatment for type 2 diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
In clinical trials, treatment proved more effective than other therapies evaluated
Cipla has reported consolidated financial results for the period ended March 31, 2022
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
The peptide-based vaccine induces a t cell-dependent response
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Subscribe To Our Newsletter & Stay Updated
